Daraxonrasib in pancreatic cancer: When progress disrupts practice

Editorial

Pancreatic ductal adenocarcinoma has long been defined by therapeutic resistance and limited progress, with genuine inflection points rare. The emergence of daraxonrasib in the second-line setting may represent one such moment. In the phase 3 RASolute 302 trial, median overall survival reached an unprecedented 13.2 months compared with 6.7 months for chemotherapy, corresponding to a hazard ratio of 0.40.¹ In a refractory population where expectations have historically been modest, this degree of benefit is striking and difficult to ignore.

Yet advances in oncology rarely simplify the landscape. More often, they reshape it. The significance of daraxonrasib lies not only in its clinical efficacy, but also in the critical questions it compels the field to address. For many years, second-line pancreatic cancer therapies have delivered limited benefit, often measured in weeks rather than months, and treatment decisions have frequently prioritized tolerability over transformative potential. Against this backdrop, the benefit observed with daraxonrasib changes the definition of what constitutes acceptable care. This shift is both clinical and psychological. Patients who previously had few meaningful options after first-line treatment now can encounter a clinically meaningful therapy capable of extending survival in a tangible way. Expectations are evolving rapidly, with clinicians moving beyond incremental gains and instead navigating a new standard that demands more substantial outcomes.

This progress, however, introduces immediate challenges for clinical research. Many second-line trials in pancreatic cancer have relied on chemotherapy-based control arms, an approach that was reasonable in the absence of clearly superior alternatives. Daraxonrasib disrupts that premise. When a therapy demonstrates a substantial survival advantage, the ethical foundation of randomization begins to weaken. Assigning patients to a treatment that is increasingly perceived as inferior becomes difficult to justify. This is not simply a theoretical concern. Patients and referring physicians are more informed and more engaged than ever, and they may be less willing to accept trial designs that do not reflect evolving standards of care. As a result, enrollment becomes more fragile and timelines less predictable, with ongoing studies at risk of becoming outdated before they are completed.

The availability of daraxonrasib through expanded access pathways adds another layer of complexity.² Providing access to promising therapies is ethically appropriate, yet it can potentially reduce participation in clinical trials. When patients can obtain a drug outside a study, the incentive to enroll diminishes. This creates a difficult balance in which real-world use begins to shape perception while controlled clinical data are still being generated. The distinction between evidence development and clinical adoption becomes less clear, complicating the interpretation of outcomes and challenging the traditional hierarchy of evidence.

The ripple effects extend across the broader treatment landscape. Many ongoing studies were designed when chemotherapy was assumed to be the backbone of care, with targeted agents layered on top in the hope of incremental benefit. The success of a single-agent pan-RAS inhibitor calls this strategy into question. If meaningful survival benefit can be achieved without chemotherapy, it becomes necessary to reconsider the value of empiric combinations. Future approaches may need to focus more closely on biological rationale and mechanistic understanding, with careful evaluation of whether additional therapies provide true incremental benefit or simply increase toxicity.

At a biological level, the promising activity of daraxonrasib also invites a reassessment of long-standing assumptions about pancreatic cancer microenvironment. The dense desmoplastic stroma has often been viewed as a primary barrier to drug delivery and a central driver of resistance, shaping many therapeutic strategies aimed at stromal modulation.³ The observed clinical activity of systemically administered allele specific tri-complex inhibitor zoldonrasib or pan-RAS inhibitor daraxonrasib achieved without explicit stromal targeting, suggests that effective inhibition of tumor-intrinsic signaling may be sufficient to drive meaningful therapeutic responses. The results show that targeting KRAS, may overcome or bypass these constraints more readily than previously appreciated. This does not diminish the importance of the tumor microenvironment, but it does point to a more nuanced understanding in which stroma is not an absolute barrier but a context that can be modified or circumvented by sufficiently potent therapies.

These encouraging results with daraxonrasib also raise the bar for emerging treatments. New agents, including allele-specific inhibitors and degraders, must now be evaluated against a more demanding benchmark. Demonstrating benefit relative to chemotherapy is no longer sufficient. Therapies will need to show either superior efficacy or clear complementary value when combined with pan-RAS inhibition. In this way, daraxonrasib acts both as a catalyst for innovation and as a filter that narrows the viable paths forward.

Beyond the current second-line indication, the next wave of evidence may prove even more practice-changing. Ongoing pivotal RASolute 303 (NCT07491445) and RASolute 304 (NCT07252232) trials seek to determine whether daraxonrasib can improve outcomes in first-line metastatic and resectable PDAC. If successful, these studies could accelerate a transition toward biomarker-driven treatment earlier in the disease course, potentially reducing dependence on conventional chemotherapy while introducing new challenges in optimizing patient selection, sequencing strategies, and resistance management.

As the drug moves into earlier lines of therapy, additional complexities will emerge. Trial design will become more challenging, particularly as crossover between treatment arms affects survival endpoints and complicates interpretation. At the same time, clinicians and patients may differ in their preferences for clinical implementation, which could influence enrollment in early-line studies. There may also be increasing pressure to move daraxonrasib into first-line or perioperative settings, potentially reshaping treatment paradigms and displacing chemotherapy as the initial standard of care. These competing forces highlight the need for flexible and adaptive trial designs that can accommodate a rapidly evolving therapeutic landscape.

Despite the impressive improvement in overall survival, most patients eventually develop resistance to daraxonrasib, as reflected by a median progression-free survival of approximately 7 months. These findings suggest that rational combination strategies will likely be required to overcome resistance and extend the durability of response. In this context, well-designed prospective clinical trials remain indispensable. Beyond establishing new standards of care, future studies will be critical for defining biologically rational combination approaches, identifying biomarkers of response and resistance, and optimizing treatment sequencing across different stages of pancreatic cancer. Perhaps the most meaningful impact of daraxonrasib lies in its effect on patient perception. Pancreatic cancer has long been associated with limited hope and difficult conversations, where expectations were constrained by experience. That narrative is beginning to change. A therapy that extends survival in a refractory setting alters not only outcomes but also expectations. Patients’ willingness to participate in trials or accept uncertainty will increasingly depend on whether those trials align with the realities of modern care.

The field now stands at an important moment. The need to provide the best available therapy to individual patients must be balanced with the need to generate evidence for future patients. This tension has always existed, but it is now more visible and more difficult to ignore. Traditional randomized trial designs may not be sufficient in this new context. Adaptive approaches, platform trials, and integration of real-world data may offer more practical and ethically sound alternatives. Incorporating daraxonrasib as a backbone rather than a comparator may help preserve both scientific rigor and patient trust.

Daraxonrasib represents both progress and disruption. It demonstrates what is possible in a disease that has long resisted change, but it also exposes the limitations of the frameworks used to evaluate and deliver new therapies. The challenge ahead is not simply to integrate this agent into clinical practice, but to adapt the broader ecosystem of pancreatic cancer research to a new reality in which progress may come faster, expectations are higher, and the balance between innovation and evidence is increasingly complex. If navigated thoughtfully, this development has the potential not only to improve outcomes but also to reshape how pancreatic cancer is perceived, researched, and managed.

Highlights:

• Daraxonrasib may redefine standards in pancreatic cancer care

• Clinical progress can disrupt established drug development pathways

• Pan-RAS inhibition challenges assumptions about stromal barriers

• Expanded access may complicate future clinical trial enrollment

• Future trials may require adaptive and backbone-based designs

Biographies

Dr. Asfar Azmi is a Professor of Oncology at Wayne State University School of Medicine. He is the Director of Pancreas Cancer Research at the NCI designated Comprehensive Cancer Center, Karmanos Cancer Institute in Detroit Michigan. Dr. Azmi made fundamental discoveries on the role of aberrant nuclear protein transport in pancreatic cancer development and drug resistance. He has made significant contributions on pre-clinical and early phase development of new drugs for pancreatic cancer and pancreatic neuroendocrine tumors particularly, nuclear export inhibitor selinexor and KRAS pathway targeted therapies. Work done by his team led to the FDA approval of selinexor in several tumor indications. His ongoing projects are focused on KRAS and Pan-Ras inhibitor resistance. Dr. Azmi has published more than 200 peer reviewed articles in prestigious journals. He is the editor of several books on drug discovery topics. Dr. Azmi is the recipient of NIH MERIT award, and awards from American Pancreatic Association, American Association for Cancer Research (AACR) and American Society of Hematology (ASH).

Dr. Philip A. Philip, M.D., Ph.D., is an internationally renowned medical oncologist specializing in gastrointestinal cancers. Currently he serves as the Director, Gastrointestinal Oncology, Co-Director, Pancreatic Cancer Center and Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute. He has led numerous breakthroughs in the areas of pancreatic and neuroendocrine tumors. His depth of expertise in research and treatment is matched by his passion for team and personalized patient care. Dr. Philip’s extensive influence in various national and international arenas includes chairing the GI committee for SWOG (the NCI-sponsored clinical trials collaborative), serving on the NCI’s Cancer Therapy Evaluation Program committee, authoring more than 200 publications, co-editing a book on pancreatic cancer and serving as an international/national lecturer with more than 400 presentations. He is an awarded professor at Wayne State University.